NOT-CA-19-049: Notice of Participation of NCI in PAR-19-156 "Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)" and PAR-19-157 "Bioengineering Research Partnerships (U01 Clinical Trial Required)"

Notice of Participation of NCI in PAR-19-156 "Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)" and PAR-19-157 "Bioengineering Research Partnerships (U01 Clinical Trial Required)"

Notice Number: NOT-CA-19-049

Key Dates
Release Date: May 6, 2019

Related Announcements

PAR-19-156
PAR-19-157

Issued by
National Cancer Institute (NCI)

Purpose

Through this Notice, the National Cancer Institute (NCI) informs potential applicants that it is participating, effective immediately, in PAR-19-156 "Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)" and PAR-19-157 "Bioengineering Research Partnerships (U01 Clinical Trial Required)".

The following sections have been updated (in italics) in both the FOAs to reflect the participation of NCI.

Part 1. Overview Information

Components of Participating Organizations

National Cancer Institute (NCI)

National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Environmental Health Sciences (NIEHS)
National Eye Institute (NEI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.394; 93.286, 93.113, 93.273, 93.866, 93.867

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Miguel Ossandon, PhD
National Cancer Institute (NCI)
Telephone: 240-276-5714
Email:[email protected]